Upon joining the study, you will be required to sign an informed consent form. This form confirms your understanding of the study and your agreement to participate.

You must be between 18 to 40 years old and in good health, as determined by a medical evaluation, including a medical history review, physical examination, and a focused cardiac ultrasound.

Before the trial begins, you will be briefed on the procedures and what to expect during the study.

Female participants must use adequate birth control if they are of childbearing potential.

During the trial, you will receive a solution called Ringer-acetat Fresenius Kabi through an intravenous slow bolus injection. This means the solution will be administered directly into your bloodstream at a controlled pace.

The solution contains several components: magnesium chloride hexahydrate, potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium acetate trihydrate.

Throughout the trial, your body’s response to the solution will be closely monitored. This includes measuring the duration of the hemodynamic effect, which refers to how the solution affects your blood flow and heart function.

The primary focus will be on the half-life of your cardiac stroke volume, which is the amount of blood pumped by your heart with each beat, relative to the baseline measurement taken before the solution was administered.

The trial is expected to conclude by July 29, 2024. Upon completion, you will be informed of any findings related to your participation.

Your involvement in the study will contribute to understanding the effects of the solution during conditions of reduced blood volume, known as hypovolemia.